Skip to content

The efficacy and mechanism of Panax notoginseng in the treatment of 'anti-platelet drug resistance'

The efficacy and mechanism of Panax notoginseng in the treatment of 'anti-platelet drug resistance'

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003884
Enrollment
Unknown
Registered
2020-09-02
Start date
2020-10-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anti-platelet drug resistance

Interventions

Sponsors

Shaanxi Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients who meet the diagnostic criteria of "Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2010" and aspirin semi resistance diagnosis issued by neurology branch of Chinese Medical Association; 2. Patients who agree to participate in the clinical trial and sign the informed consent form; 3. Patients aged 45-65 years, with no gender limit and taking single antiplatelet drugs; 4. Patients with Essen stroke risk score <= 3; 5. Patients who no longer use traditional Chinese medicine with the function of promoting blood circulation and removing blood stasis in the observation period.

Exclusion criteria

Exclusion criteria: 1. Patients with transient ischemic attack and cerebral infarction need double antibody; 2. Patients with cerebral infarction, cerebral hemorrhage, cerebral arteritis, brain tumor, brain trauma, brain parasitic disease and rheumatic heart disease; 3. Patients with bleeding tendency or severe bleeding within 3 months; 4. Patients with severe liver, kidney, hematopoietic and metabolic diseases; 5. Patients with disabilities prescribed by law (blindness, deafness, dumb, mental retardation, mental disorder and physical disability caused by other reasons) affect the evaluators of neurological impairment; 6. Patients who are suspected or have a history of alcohol and drug abuse, or other situations that, according to the judgment of the researchers, have the possibility of reducing or complicating the enrollment; 7. Patients who are participating in other clinical trials or have participated in other drug clinical trials within 3 months.

Design outcomes

Primary

MeasureTime frame
Platelet aggregation function (PAgT);Thromboxane A2;Prostacyclin (PGI2);

Secondary

MeasureTime frame
Adenosine diphosphate;

Countries

China

Contacts

Public ContactDongling Liu

Xi'an Hospital of Traditional Chinese Medicine

xaldl2006@126.com+86 13772077468

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026